Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
2013
Background There is a well-acknowledged need for an effective AIDS vaccine that protects against HIV-1 infection or limits in vivo
viral replication. The objective of these studies is to develop a replication-competent, vaccine vector based on the adenovirus serotype 4 (Ad4) virus expressing HIV-1 envelope (Env) 1086 clade C glycoprotein. Ad4 recombinant vectors expressing Env gp160 (Ad4Env160), Env gp140 (Ad4Env140), and Env gp120 (Ad4Env120) were evaluated.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
65
References
22
Citations
NaN
KQI